Can we reliably identify drug targets at the proteome scale using AlphaFold based docking or generative AI?

Read full text Summarise with VIRAT
Authors: Xiaodong Xing, Yi Guo, Ting Wang, Yuan Fu
Cited by: 0
References: 37

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Drug target identification is important for drug repurposing, follow-up studies in drug development, and understanding drug side effects. Essentially, the pharmacological effect of drug is determined by the interaction between the drug and its target, and the interaction is in turn governed by the three-dimensional structures. With the advent of AlphaFold, we now have access to nearly complete proteome-scale structural data for any species. This opens the possibility of systematically identifying drug targets in silico using current docking and modeling tools. In this study, we benchmarked the performance of several docking tools in proteome-wide blind reverse docking and also evaluated the utility of generative AI, including AlphaFold3, in drug target prediction. Our results show that, with appropriate tool selection and preparation of the structural dataset, drug targets can be effectively enriched. Notably, AlphaFold3 alone enables reasonably accurate identification of potential targets. As a proof-of-concept, we identified a previously unreported binding target for the clinical drug palbociclib. This work provides practical insight into how we can utilize structural data for drug target discovery in the post-AlphaFold era.

Fields of Study & Subjects

Computational Drug Discovery Methods Protein Structure and Dynamics Protein Degradation and Inhibitors

Publication details

Journal / source
Artificial Intelligence in the Life Sciences
Volume
9
Pages
100167–100167
Publication date
26 March 2026
Language
EN